TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2616 Stock 12 Month Forecast
There Are No Analyst Ratings for HK:2616 In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
2616 Financial Forecast
2616 Earnings Forecast
Next quarter’s earnings estimate for 2616 is -HK$0.01 with a range of -HK$0.01 to -HK$0.01. The previous quarter’s EPS was -HK$0.24. 2616 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 2616 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2616 is -HK$0.01 with a range of -HK$0.01 to -HK$0.01. The previous quarter’s EPS was -HK$0.24. 2616 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 2616 has Performed in-line its overall industry.
2616 Sales Forecast
Next quarter’s sales forecast for 2616 is HK$295.51M with a range of HK$295.51M to HK$295.51M. The previous quarter’s sales results were HK$53.12M. 2616 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.09% of the time in the same period. In the last calendar year 2616 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2616 is HK$295.51M with a range of HK$295.51M to HK$295.51M. The previous quarter’s sales results were HK$53.12M. 2616 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.09% of the time in the same period. In the last calendar year 2616 has Performed in-line its overall industry.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$6.25→HK$7.05
Buy
32.02%
Upside
Reiterated
10/21/25
Goldman Sachs Keeps Their Buy Rating on CStone Pharmaceuticals (2616)
Unknown Analyst
TFI Asset Management
Not Ranked
TFI Asset Management
HK$12.55
Buy
135.02%
Upside
Reiterated
08/18/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$6.25→HK$7.05
Buy
32.02%
Upside
Reiterated
10/21/25
Goldman Sachs Keeps Their Buy Rating on CStone Pharmaceuticals (2616)
Unknown Analyst
TFI Asset Management
Not Ranked
TFI Asset Management
HK$12.55
Buy
135.02%
Upside
Reiterated
08/18/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +29.50% per trade.
Copying PerPlexity Health Care HK's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.50% per trade.
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2616 Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Oct 25
Nov 25
Strong Buy
1
0
0
0
0
Buy
0
1
2
3
2
Hold
3
7
6
18
18
Sell
0
0
0
3
5
Strong Sell
0
0
0
0
0
total
4
8
8
24
25
In the current month, 2616 has received 2Buy Ratings, 18Hold Ratings, and 5Sell Ratings. 2616 average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
2616 Stock Forecast FAQ
What is HK:2616’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2616’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2616, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CStone Pharmaceuticals a Buy, Sell or Hold?
Currently, no data Available
What is CStone Pharmaceuticals’s share price target?
Currently, no data Available
What do analysts say about CStone Pharmaceuticals?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of CStone Pharmaceuticals?
To buy shares of HK:2616, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.